Carisma Therapeutics (CARM) Competitors

Mural Oncology (NASDAQ:MURA) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, community ranking, earnings, risk, institutional ownership, dividends and valuation.

Which has more volatility & risk, MURA or CARM?

Mural Oncology has a beta of 3.9, indicating that its share price is 290% more volatile than the S&P 500. Comparatively, Carisma Therapeutics has a beta of 1.56, indicating that its share price is 56% more volatile than the S&P 500.

Do analysts prefer MURA or CARM?

Mural Oncology currently has a consensus price target of $16.00, indicating a potential upside of 295.06%. Carisma Therapeutics has a consensus price target of $4.94, indicating a potential upside of 966.95%. Given Carisma Therapeutics' higher possible upside, analysts clearly believe Carisma Therapeutics is more favorable than Mural Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mural Oncology	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25
Carisma Therapeutics	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.43

Does the MarketBeat Community believe in MURA or CARM?

Carisma Therapeutics received 12 more outperform votes than Mural Oncology when rated by MarketBeat users. However, 100.00% of users gave Mural Oncology an outperform vote while only 77.27% of users gave Carisma Therapeutics an outperform vote.

Company	Underperform	Outperform
Mural Oncology	Outperform Votes 5 100.00%	Underperform Votes No Votes
Carisma Therapeutics	Outperform Votes 17 77.27%	Underperform Votes 5 22.73%

Do institutionals & insiders have more ownership in MURA or CARM?

80.2% of Mural Oncology shares are held by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are held by institutional investors. 0.1% of Mural Oncology shares are held by insiders. Comparatively, 12.6% of Carisma Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Which has higher valuation and earnings, MURA or CARM?

Carisma Therapeutics has higher revenue and earnings than Mural Oncology. Mural Oncology is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mural Oncology	N/A	N/A	-$207.45M	-$9.14	-0.44
Carisma Therapeutics	$14.92M	1.30	-$86.88M	-$1.56	-0.30

Does the media favor MURA or CARM?

In the previous week, Mural Oncology had 2 more articles in the media than Carisma Therapeutics. MarketBeat recorded 3 mentions for Mural Oncology and 1 mentions for Carisma Therapeutics. Mural Oncology's average media sentiment score of 0.21 beat Carisma Therapeutics' score of 0.00 indicating that Mural Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mural Oncology	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Carisma Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is MURA or CARM more profitable?

Mural Oncology has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -314.78%. Mural Oncology's return on equity of -70.10% beat Carisma Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mural Oncology	N/A	-70.10%	-61.30%
Carisma Therapeutics	-314.78%	-957.20%	-96.39%

Summary

Mural Oncology beats Carisma Therapeutics on 10 of the 16 factors compared between the two stocks.